Brain versus peripheral angiotensin II receptors in hypovolaemia: behavioural and cardiovascular implications - PubMed

Review

Brain versus peripheral angiotensin II receptors in hypovolaemia: behavioural and cardiovascular implications

L A De Luca Jr et al. Clin Exp Pharmacol Physiol. 2000 May-Jun.

Abstract

1. Angiotensin (Ang)II is involved in responses to hypovolaemia, such as sodium appetite and increase in blood pressure. Target areas subserving these responses for AngII include the cardiovascular system in the periphery and the circumventricular organs in the brain. 2. Conflicting data have been reported for the role of systemic versus brain AngII in the mediation of sodium appetite. 3. The role for systemic AngII and systemic AngII receptors in the control of blood pressure in hypovolaemia is well established. In contrast with systemic injections, i.c.v injections of AngII non-peptide AT1 and AT2 receptor antagonists, such as losartan and PD123319, do not reduce arterial pressure in sodium-depleted (furosemide injection plus removal of ambient sodium for 24 h) rats. Thus, brain AngII receptors are likely not important for cardiovascular responses to hypovolaemia induced by sodium depletion. 4. Intracerebroventricular injections of losartan or PD123319 increase arterial pressure when injected at relatively high doses. This hypertensive effect is unlikely to be an agonist effect on brain AngII receptors. Increases in arterial pressure produced by i.c.v. losartan are attenuated by lesions of the tissue surrounding the anterior third ventricle (AV3V). The hypertensive effect of i.c.v. AngII is abolished by lesions of the AV3V. 5. Hypertension induced by AngII receptor antagonists is consistent with hypotension induced by AngII acting in the brain. However, the full physiological significance of this hypotensive effect mediated by brain AngII receptors remains to be determined.

Similar articles

• Role of the angiotensin II AT2-subtype receptors in the blood pressure-lowering effect of losartan in salt-restricted rats.

  Gigante B, Piras O, De Paolis P, Porcellini A, Natale A, Volpe M. Gigante B, et al. J Hypertens. 1998 Dec;16(12 Pt 2):2039-43. doi: 10.1097/00004872-199816121-00027. J Hypertens. 1998. PMID: 9886894

• Role of AT2 receptors in the cardiovascular events following microinjection of angiotensin II into the superior colliculus of anaesthetised rats.

  D'Amico M, Di Filippo C, Rossi F, Warner TD. D'Amico M, et al. Naunyn Schmiedebergs Arch Pharmacol. 1998 Feb;357(2):121-5. doi: 10.1007/pl00005145. Naunyn Schmiedebergs Arch Pharmacol. 1998. PMID: 9521484

• Role of AT2 receptors in angiotensin II-stimulated contraction of small mesenteric arteries in young SHR.

  Touyz RM, Endemann D, He G, Li JS, Schiffrin EL. Touyz RM, et al. Hypertension. 1999 Jan;33(1 Pt 2):366-72. doi: 10.1161/01.hyp.33.1.366. Hypertension. 1999. PMID: 9931131

• Angiotensin II receptors.

  Ardaillou R. Ardaillou R. J Am Soc Nephrol. 1999 Jan;10 Suppl 11:S30-9. J Am Soc Nephrol. 1999. PMID: 9892138 Review.

• Aminopeptidase A, which generates one of the main effector peptides of the brain renin-angiotensin system, angiotensin III, has a key role in central control of arterial blood pressure.

  Reaux A, Iturrioz X, Vazeux G, Fournie-Zaluski MC, David C, Roques BP, Corvol P, Llorens-Cortes C. Reaux A, et al. Biochem Soc Trans. 2000;28(4):435-40. Biochem Soc Trans. 2000. PMID: 10961935 Review.

Cited by

• Participation of the angiotensinergic and vasopressinergic mechanisms in the maintenance of cardiorespiratory parameters in sodium depleted rats.

  Cardoso F, Fávero MT, Veríssimo NV, Furtado Menezes M, Menani JV, de Paula PM. Cardoso F, et al. Heliyon. 2022 Dec 13;8(12):e12221. doi: 10.1016/j.heliyon.2022.e12221. eCollection 2022 Dec. Heliyon. 2022. PMID: 36582730 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal